# Thymosin Alpha-1: Research Overview — Physician-Only Peptides > A literature summary of Thymosin Alpha-1 (thymalfasin, Tα1): mechanism at the innate-adaptive immune interface, sepsis trial data, cancer immunotherapy use, and regulatory status across more than 35 countries. An N-terminally acetylated 28-amino-acid thymic peptide approved in more than 35 countries — and the subject of the largest, most rigorous sepsis RCT yet, which came back null. ## The short version Thymosin Alpha-1, also known as thymalfasin or Tα1, is a 28-amino-acid peptide originally isolated from calf thymus in 1977 [7]. Its N-terminal acetyl group — a small chemical cap on one end — is essential for its activity. In broad terms, it is an *immunomodulator*: it can push a weakened immune response upward in immunosuppressed patients, while also activating a counterbalancing tolerogenic arm to prevent runaway inflammation [6]. Here is the honest picture. Thymosin Alpha-1 is approved as a drug (thymalfasin) in more than 35 countries and has been used clinically for chronic viral hepatitis, cancer immunotherapy adjunction, and sepsis [2]. Its safety record over four decades is reassuring — local injection-site reactions are the main side effect [2]. However, the largest, most rigorous sepsis trial ever run — a phase-3, double-blind, placebo-controlled study of 1,106 adults — found no significant 28-day mortality benefit [1]. That null result tempers earlier smaller positive studies. This page summarizes what was studied; it is not medical advice and lists no human dose. ## What it is Thymosin Alpha-1 is a *28-amino-acid, N-terminally acetylated thymic polypeptide*. Its full sequence is Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn. It is highly acidic, contains no aromatic residues, and has no disulfide bonds. In the body, it is cleaved from a 113-amino-acid precursor called prothymosin alpha; the N-terminal acetylation is essential for biological activity. The synthetic pharmaceutical version, thymalfasin, is sequence-identical to the natural peptide and is the form used in all modern clinical trials. This is not the same compound as thymosin beta-4 (the parent protein of TB-500), thymalin (a bovine thymic complex), thymopentin, or thymulin. The names are similar; the molecules are chemically and pharmacologically distinct. ## How it works Thymosin Alpha-1 acts at the *innate-adaptive immune interface*. Its best-characterized actions operate through two complementary arms. The first arm is *immunostimulatory*. Thymosin Alpha-1 signals through Toll-like receptors TLR2 and TLR9 on dendritic cells and monocytes, promoting their maturation, driving IL-12 production, and enhancing antigen presentation. This activity leads to T-cell maturation and Th1 polarization — the side of the immune system responsible for clearing intracellular infections and mounting cytotoxic T-cell responses. The second arm is *tolerogenic*. The same TLR9 and type I interferon signaling cascade also activates the indoleamine 2,3-dioxygenase (IDO) pathway in dendritic cells, which produces tryptophan catabolites and interleukin-10, generating regulatory T cells alongside the Th1 priming [6]. In plain terms: Thymosin Alpha-1 can simultaneously rev up effector immunity in depleted patients and put a regulatory brake on hyperinflammation — a dual profile that helps explain why it has been studied across very different immune states. ## What the research shows *Original isolation.* In 1977, Goldstein and colleagues purified Thymosin Alpha-1 from calf thymus (thymosin fraction 5) and determined its complete 28-amino-acid sequence with N-terminal acetylation [7]. This foundational biochemical characterization set the stage for synthetic production and clinical study. *Mechanism.* The IDO-pathway study established the dual immunomodulatory signature in mouse and human dendritic cells: Th1 priming coexists with an IDO-dependent regulatory T-cell-generating environment, mediated by TLR9 and type I interferon receptor [6]. *Sepsis — ETASS.* In the multicenter ETASS randomized controlled trial of 361 patients with severe sepsis, 28-day all-cause mortality was 26.0% in the Thymosin Alpha-1 group versus 35.0% in controls — an absolute reduction of about 9 percentage points that did not reach conventional statistical significance (nonstratified P=0.062; log-rank P=0.049) [5]. HLA-DR expression on monocytes, a marker of immune competence, improved in the treatment group. *Sepsis — TESTS.* The definitive test came in the phase-3 TESTS trial (1,106 adults, 22 centres, double-blind): Thymosin Alpha-1 produced 23.4% 28-day mortality versus 24.1% for placebo, hazard ratio 0.99 (95% CI 0.77-1.27), P=0.93 — a clearly null result [1]. This is the largest and most rigorous sepsis trial yet run and materially tempers the earlier positive but smaller ETASS signal. *COVID-19.* A retrospective review of 76 patients with severe COVID-19 found Thymosin Alpha-1 treatment associated with significantly reduced mortality (11.11% vs 30.00%, P=0.044), increased blood T-cell numbers in lymphocytopenic patients, and reduced PD-1 and Tim-3 expression on CD8+ T cells, reversing T-cell exhaustion [3]. This is a retrospective cohort, not a controlled trial. *Cancer immunotherapy.* A reappraisal of the oncology evidence positions Thymosin Alpha-1 as a combination-protocol immunomodulator studied alongside chemo- and immunotherapies in melanoma, hepatocellular carcinoma, and lung cancer. It may help "turn cold tumours hot" by activating antigen presentation while also moderating checkpoint-inhibitor toxicity via mucosal homeostasis restoration [4]. *Safety and dosing overview.* A 2020 comprehensive review across four decades of clinical literature documents the standard subcutaneous dose range as 0.8 to 6.4 mg (multiple-dose regimens reaching 1.6–16 mg), widespread international approval, and a benign safety profile dominated by mild local injection-site reactions [2]. ## Reported effects, cautions & safety Thymosin Alpha-1 has an unusually long and wide safety record for a research-context peptide. The cautions below come directly from the cited literature. **Anecdotal community reports (labeled: not clinical evidence)** People who have used Thymosin Alpha-1 outside approved settings most commonly report: fewer or shorter colds over a season; faster recovery from illness or periods of feeling run-down; a general sense of immune resilience; and more stable energy during recovery from chronic illness. On the tolerability side, most describe it as unremarkable — one of the easier peptides to handle. Adverse reports include mild injection-site redness, itching or stinging (the most common complaint); occasional transient flu-like or achy feelings early in a course; and rare low-grade headache or tiredness. A common report is simply noticing no effect at all, which is consistent with an immune-modulatory peptide whose actions are biochemical rather than felt. Some users note cost and limited US availability as practical obstacles, and informed community members flag the 2025 null sepsis headline as a reason for tempered expectations. *These are anecdotal, not clinical evidence. No dose, schedule or health claim is implied.* **Cited safety cautions** - *Theoretical caution in autoimmune disease.* Thymosin Alpha-1 promotes dendritic-cell maturation, Th1 polarization and cytotoxic T-cell activity. In established autoimmunity, broadly enhancing effector immunity is a theoretical concern, even though the peptide's IDO-driven regulatory arm provides a counterbalance and circulating Tα1 levels are actually reduced in several autoimmune diseases [2]. - *Theoretical caution in solid-organ transplant recipients.* Transplant recipients are deliberately immunosuppressed; a peptide that reverses T-cell exhaustion, boosts antigen presentation and restores T-cell maturation could work against intentional immunosuppression [6]. - *Limited pregnancy and lactation data.* Four decades of clinical data come from hepatitis, sepsis, cancer and immune-reconstitution populations; dedicated pregnancy and lactation studies are absent, so fetal or infant risk cannot be characterized [2]. - *Injection-site reactions are the main expected adverse effect.* Local redness, itching, burning or discomfort at the subcutaneous injection site are the dominant adverse events across large post-marketing surveillance; organ toxicity has not been documented at studied doses [2]. - *Efficacy expectations should be tempered by null high-quality trial data.* The phase-3 TESTS trial (1,106 adults, P=0.93) is a direct caution against assuming benefit outside the settings where the signal is strongest — primarily chronic viral hepatitis [1]. - *US non-approval and research-grade quality risk.* Thymosin Alpha-1 is not FDA-approved for marketing in the US. Research-grade material obtained outside the regulated drug-quality chain provides no guarantee of purity, actual content, sterility or identity [2]. ![Thymosin Alpha-1 immune-signaling illustration in cold emerald night palette](/images/thymosin-alpha-1.webp) ## Where it fits in immune research Among the two peptides on this desk, Thymosin Alpha-1 is the clinically established one — approved internationally, studied in large RCTs, backed by four decades of human safety data. The honest summary is that its record is widest in chronic viral hepatitis and cancer-adjuvant settings, mixed in sepsis (with the largest trial null), and preliminary in COVID-19 [1][2][3][4]. Its mechanism is well understood at the dendritic-cell level, and its safety profile is among the best documented of any research-context peptide [2]. Read alongside [Thymulin](/thymulin), which is earlier-stage and structurally unrelated, Thymosin Alpha-1 illustrates what it looks like when a thymic peptide moves through decades of clinical development — and where even a well-studied compound can face a pivotal null result. See the [comparison page](/compare) for how it lines up against Thymulin. --- A literature digest of thymic immune peptide research — every claim is numbered, every caution is cited, and nothing here is medical advice.